Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds


You May Also Like

Horizon Pharma plc to Participate in Investor Conference in December

DUBLIN, Ireland, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical ...

Successful US patent strategy – Oncology Ventures Irofulven Claims Accepted

Hoersholm; May 29th, 2017 - Medical Prognosis Institute (MPI:ST) today announced that Oncology Venture ...